Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis.

[1]  B. Nilsson,et al.  The significance of serum CA 125 elevation in malignant and nonmalignant diseases. , 2002, Gynecologic oncology.

[2]  K. Adams,et al.  Surrogate End Points in Heart Failure , 2002, The Annals of pharmacotherapy.

[3]  W. Kübler,et al.  Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. , 2002, European heart journal.

[4]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[5]  P. Ponikowski,et al.  The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. , 2000, Journal of the American College of Cardiology.

[6]  A. Campana,et al.  CA125 production by the peritoneum: in-vitro and in-vivo studies. , 2000, Human reproduction.

[7]  A. Sevinç,et al.  Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids. , 2000, Gynecologic oncology.

[8]  R. Klapdor,et al.  CA 125 and its relation to cardiac function. , 1999, American heart journal.

[9]  M. Widschwendter,et al.  Regulation of CA 125 Expression in Cultured Human Carcinoma Cells , 1998, The International journal of biological markers.

[10]  T. O’Brien,et al.  More than 15 Years of CA 125: What is Known about the Antigen, Its Structure and Its Function , 1998, The International journal of biological markers.

[11]  High serum levels of CA125 and interleukin‐6 in a patient with Ki‐1 lymphoma , 1997, British journal of haematology.

[12]  O. Dapunt,et al.  Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. , 1997, Anticancer research.

[13]  G. MacGowan,et al.  Circulating interleukin-6 in severe heart failure. , 1997, The American journal of cardiology.

[14]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[15]  A. Giordano,et al.  Doppler-Derived Mitral Deceleration Time of Early Filling as a Strong Predictor of Pulmonary Capillary Wedge Pressure in Postinfarction Patients with Left Ventricular Systolic Dysfunction , 1994, Journal of the American College of Cardiology.

[16]  Katsuya Kobayashi,et al.  Usefulness of serum CA125 measurement for monitoring pericardial effusion. , 1993, Japanese circulation journal.

[17]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[18]  S. Bates,et al.  Clinical applications of serum tumor markers. , 1991, Annals of internal medicine.

[19]  J. Bidart,et al.  Elevation of CA 125 in patients with benign and malignant ascites , 1987, Cancer.

[20]  N. Nanda,et al.  Color Doppler assessment of mitral regurgitation with orthogonal planes. , 1987, Circulation.

[21]  R. Bast,et al.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.